Carvedilol improves survival in HFrEF beyond what metoprolol tartrate achieves in some comparisons. Beyond beta-1 blockade, which pharmacological properties distinguish carvedilol?

• A Alpha-1 blockade with antioxidant and antiproliferative actions from its carbazole structure ✓
• B Selective intrinsic sympathomimetic activity preserving resting heart rate
• C Pure alpha-2 agonism with peripheral vasodilation
• D Blockade of the late inward sodium current similar to ranolazine

Explanation

Carvedilol blocks beta-1, beta-2, and alpha-1 receptors, producing vasodilation that reduces afterload, while its carbazole core confers antioxidant and antiproliferative effects that limit oxygen free radical injury and vascular smooth muscle proliferation. These extras are cited as contributing to its mortality benefit in heart failure trials. Intrinsic sympathomimetic activity is a feature of pindolol and is actually undesirable in HFrEF. Late sodium current inhibition belongs to ranolazine, not carvedilol.

Reference: Katzung's Basic and Clinical Pharmacology, 15th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.